Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Local biotech entrepreneurs and investors are seeing signs that the four-year "biotech winter" is finally thawing, though ...

We all know someone waiting on a medical breakthrough. It could be a parent battling a chronic illness, a colleague pushing ...

11 companies raised US$4 billion in Hong Kong in the first three weeks of 2026, with hundreds more lining up to list, Bonnie ...

VanEck Biotech ETF gets a Hold rating as top holdings face low growth, patent cliffs, and rich valuation vs. peers. Click to read my latest analysis of BBH.

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and biotechnology industries think about drug development, regenerative medicine, ...

Uncover the systematic approach to biotech firm valuation using DCF. Equip yourself with the knowledge to gauge company ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...